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WHAT THIS PAPER ADDS
 The technology of endovascular aneurysm repair (EVAR) for abdominal aortic aneurysms (AAAs) is a dynamic, ever-changing
endeavour. The challenge is to decrease complications and re-interventions while safely treating more complex anatomy. As
improved devices become available and operators become more proﬁcient with endovascular techniques, EVAR outcomes change.
In order to make balanced judgement about the management of AAAs, it important to augment the knowledge base about EVAR in
contemporary practice with the latest generation devices. The Endurant Stent Graft Natural Selection Global Postmarket Registry
(ENGAGE) has been designed to closely monitor the real-world performance of the Endurant Stent Graft System. Unprecedented in
size, scope and geographic representation, it represents a combined experience of 79 sites worldwide.a r t i c l e i n f o
Article history:
Received 24 March 2012
Accepted 2 July 2012
Available online 24 July 2012
Keywords:
Abdominal aortic aneurysm (AAA)
Endovascular aneurysm repair (EVAR)
Endurant
ENGAGE
Outcome* Corresponding author. J.A.W. Teijink, Department o
Hospital, Michelangelolaan 2, P.O. Box 1350, 5602 ZA
Tel.: þ31 040 239 7155; fax: þ31 040 244 3370.
E-mail address: joep.teijink@cze.nl (J.A.W. Teijink)
1078-5884/$ e see front matter  2012 European So
http://dx.doi.org/10.1016/j.ejvs.2012.07.005a b s t r a c t
Objective: The ENGAGE registry was undertaken to examine the real-world outcome after endovascular
abdominal aortic aneurysm (AAA) repair (EVAR) with the Endurant Stent Graft in a large, contemporary,
global series of patients.
Methods: From March 2009 to April 2011, 1262 AAA patients (89.6% men; mean age 73.1 years, range
43e93 years) were enrolled from 79 sites in 30 countries and treated with Endurant. Results are
described following the reporting standards for EVAR. Follow-up data were tabulated for all 1262
patients at a 30-day follow-up and for the ﬁrst 500 patients at a 1-year follow-up.
Results: Intra-operative technical success was achieved in 99.0% of cases. Within 30 days, adverse events
were reported in 3.9% of patients, including a 1.3% mortality rate. Type-I or eIII endoleaks were identiﬁed
in 1.5% of cases. Estimated overall survival, aneurysm-related survival and freedom from secondary
interventions at 1 year were 91.6%, 98.6% and 95.1%, respectively. At 1 year, aneurysm size increased
5 mm in 2.8% and decreased 5 mm in 41.3% of cases.
Conclusion: Early results from this real world, global experience are promising and indicate that endo-
vascular AAA repair with the Endurant Stent Graft is safe and effective across different geographies and
standards of practice. Longer-term follow-up is necessary to assess durability of these results.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.f Vascular Surgery, Catharina
Eindhoven, The Netherlands.
.
ciety for Vascular Surgery. PublisheAbdominal aortic aneurysms (AAAs) are a signiﬁcant health
challenge with an estimated incidence of 20e40 cases per
100 000 population per year. Patients present with varying levels
of risk due to aneurysm size, age and concurrent co-morbidities.1
Since Parodi2 and Volodos3 published the ﬁrst transfemorald by Elsevier Ltd. All rights reserved.
Table 1
Endurant indications for use.
One of the following criteria:
- Infrarenal neck length 10 mm with non-signiﬁcant calciﬁcation,
and/or non-signiﬁcant thrombus in combination with 45 suprarenal
angulation and 60 infrarenal angulation.
- Infrarenal neck length 15 mm with non-signiﬁcant calciﬁcation
and/or non-signiﬁcant thrombus in combination with 60 suprarenal
angulation and 75 infrarenal angulation.
And all of the following criteria:
- Adequate iliac/femoral access
- Proximal AAA neck diameter 19 mm and 32 mm
- Distal iliac ﬁxation site diameter 8 mm and 25 mm
- Distal non-aneurysmal iliac ﬁxation length 15 mm bilaterally
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endovascular aneurysm repair (EVAR) has continually improved.
Today, this approach is a generally accepted alternative to
conventional open surgical repair due to reductions in perioper-
ative mortality and morbidity, blood loss, use of the intensive care
unit (ICU) and length of hospital stay.4 Several randomised trials
have conﬁrmed these beneﬁts,5e7 and one trial conﬁrmed these
beneﬁts except for perioperative mortality and major adverse
events.8
The success of EVAR, however, is dependent upon patient-
speciﬁc factors, including morphology and dimensions of the
aneurysm. Severely angulated or short infrarenal aortic necks and
small, tortuous or calciﬁed iliac arteries are related to adverse
EVAR outcomes,9 and thus guidelines for commercially available
stent grafts indicate use within a speciﬁc range of anatomy. A
substantial portion of AAA patients fall outside these generally
accepted inclusion criteria,10 and their advanced disease state or
major co-morbidities present a high risk for open surgical repair.
Therefore, there is a need for improved stent grafts and endo-
vascular techniques to decrease complications and increase
eligibility.
Medtronic Endovascular (Santa Rosa, CA, USA) designed its
latest generation product, the Endurant Stent Graft System, to
address the limitations of previous stent graft designs. A small
amplitude M-shaped proximal stent was designed to improve
sealing at the proximal neck while potentially allowing for greater
sizing ﬂexibility. Radial strength was also improved while allowing
a lower-proﬁle delivery system. The Endurant Stent Graft System
received CE mark approval in July 2008 and Food and Drug
Administration (FDA) approval in December 2010. After a safety
assessment trial conducted in Europe,11 the Endurant Stent Graft
Natural Selection Global Postmarket Registry (ENGAGE) was
undertaken to quantify the performance of this recently released
endograft within the context of contemporary, real-world use.
Herein, we report the perioperative and 1-year results of this




Between March 2009 and April 2011, eligible patients from 79
sites in 30 countries (Appendix) were enrolled in the ENGAGE
registry. The study protocol strongly encouraged consecutive
enrolment of at least ﬁve patients in a row to minimise selection
bias. Ruptured AAAs were not considered for enrolment into
ENGAGE. Prior to the index procedure, computed tomography
angiography (CTA) imaging of the abdomen and pelvis was
undertaken to determine the morphological eligibility for elective
endovascular treatment with an Endurant Stent Graft. To reﬂect
the real-world clinical practice, eligibility criteria for participation
were kept comprehensive. Although the study design included
that individual morphological variables (proximal neck diameter
and length, infrarenal and suprarenal angulation and distal iliac
ﬁxation diameter and length) were consistent with Endurant’s
Instructions for Use (IFU) (Table 1), enrolment of patients who fell
outside the IFU guidance was accepted. Patients considered
unlikely to adhere to the follow-up regimen and patients with
concurrent trial participation were excluded from study enrol-
ment. A signed consent for authorisation of data release was
required. The trial was conducted according to the Declaration of
Helsinki and the International Conference on Harmonization (ICH)
Good Clinical Practice (GCP) guidelines, and approved by local
medical ethics committees.Study procedure
Technical speciﬁcations of the Endurant Stent Graft System have
been published previously.11,12 Preoperatively, each patient had
a customised planmadewith respect to stent diameters and length,
dependent on their aortic and iliac dimensions. For optimal sealing,
it was advised to oversize the stent diameter by approximately 20%
based on inner vessel diameter. All endovascular procedures were
performed under ﬂuoroscopic control. Local, regional or general
anaesthetics, antibiotics and heparin were administered according
to each site’s standard regimen. Arterial access was conducted by
operator’s preference. If necessary, coil embolisation of the hypo-
gastric or inferior mesenteric artery, or other adjunctive procedures
were performed and documented before or during the implant
procedure. A completion angiogram was performed to document
the status after stent graft implantation.
Imaging and follow-up
Follow-up was planned according to standard practice at each
clinical site, with the exception of the requirement for 30-day and
1-year imaging studies No speciﬁc tests or procedures that fell
outside a site’s standard regimen for AAA follow-up were required.
Diagnostic images were analysed at both time points for technical
outcomes and AAA changes. The presence of endoleak was classi-
ﬁed by type and recorded as well as changes in aneurysm size.
‘End’ points and deﬁnitions
The ENGAGE registry was designed to assess effectiveness of the
Endurant Stent Graft at 12 months post-implantation, with follow-
up extended to 5 years. This manuscript describes the initial
procedural data and outcomes, the technical observations, adverse
events and major adverse events (MAEs) within 30 days and 12
months, along with stent graft migration and aneurysm expansion
(>5 mm) between 30 days and 12 months.
The primary effectiveness ‘end’ point was the initial procedural
success, a composite of technical success and clinical success at the
time of the index procedure. Technical success was deﬁned as
successful delivery and deployment of the Endurant Stent Graft in
the planned positionwithout unintentional coverage of one or both
internal iliac arteries or visceral aortic branches and with successful
removal of the delivery system. In the case of primary conversion,
technical success failed. Initial clinical success was deﬁned as
technical success without intra-operative death or presence of
a type-I/III endoleak at the conclusion of the index procedure.
The secondary ‘end’ points consisted of technical observations,
adverse events and MAE. Technical observations included: stent
graft kinking; stent graft wire form fracture; suprarenal bare stent
fracture or detachment from fabric; occlusion (deﬁned as 100%
obstruction); stenosis (deﬁned as partial obstruction); and
Table 2
Patient demographics and risk factors (ITT analysis).
Variable N ¼ 1262a





Class I 6.1% (77/1261)
Class II 41.8% (527/1261)
Class III 41.5% (523/1261)
Class IV 10.6% (134/1261)
Symptoms
A-symptomatic AAAc 83.9% (1059/1262)
Symptomatic AAAc 16.1% (203/1262)
Indication by AAAc diameter
>5 cm 88.1% (1112/1262)
4e5 cm (0.5 cm increase in last 6 months) 6.3% (79/1262)
1.5x reference infrarenal aorta 2.9% (42/1262)
Other 2.3% (29/1262)
Risk factors






Myocardial infarction (MI) 26.3% (318/1210)
Arrhythmia 16.0% (198/1234)
Coronary artery disease (CAD) 34.6% (422/1218)
Cardiac revascularisation 27.1% (337/1244)
Pulmonary disease 25.1% (311/1241)
Renal insufﬁciency 15.3% (191/1251)
Cerebrovascular disease
Transient ischaemic attack (TIA) 4.9% (61/1249)
Cerebral vascular accident (CVA) 5.3% (67/1255)
Gastro-intestinal complications 19.5% (246/1261)
a Denominator differs when there are missing values.
b American Society of Anesthaesiologists.
c Abdominal aortic aneurysm.
Table 3
Baseline aneurysm characteristics (ITT analysis).
Variable Mean  SD N ¼ 1262
(range)
Maximum AAAa diameter (mm) 60.3  11.7 (30e118)
Proximal neck diameter (mm) 23.7  3.6 (15e45b)
Proximal non-aneurysmal neck length (mm) 27.0  12.4 (0c e 80)
Distal iliac ﬁxation site diameter (mm)
Right 14.1  3.6 (2e29)
Left 13.8  3.5 (6e30)
Infrarenal neck angle () 30.3  23.8 (0e130)
60 89.8%
60e75 6.0%
Suprarenal neck angle () 18.8  18.5 (0e120)
45 92.5%
45e60 4.5%
a Abdominal aortic aneurysm.
b Upper range of 45mm: Tapered aortic neck, with a proximal diameter of 45mm,
a diameter of 22 mm immediately above the aneurysm and a 15 mm
non-aneurysmal neck length.
c Lower range of 0 mm: Case performed with a “chimney technique”.
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aneurysm rupture and secondary interventions were stated as
adverse events. All-cause mortality, bowel ischaemia, myocardial
infarction, paraplegia, renal failure (requiring dialysis or elevated
serum creatinine two times baseline value), respiratory failure
(need for >24 h mechanical ventilation postoperatively or reintu-
bation for any reason), stroke and procedural blood loss 1000 cc
were noted as MAEs. All deaths within 30 days postoperative were
judged to be aneurysm-related. All-cause mortality, aneurysm-
related mortality and secondary procedures were separately
assessed as 1-year KaplaneMeier estimates.
Data management, quality control and statistical analysis
Data collected on each patient were recorded on a web-based
electronic case report form (Veracity Clinical Asset Manage-
ment, MERGE Healthcare, Chicago, IL, USA) to ensure reliable data
collection, data management, secure authentication and trace-
ability. Data were entered by, or under supervision of, sites’ prin-
cipal investigators. Data management and biostatistical analysis
were performed by the Medtronic Biostatistics & Data-
Management Department (Santa Rosa, CA, USA). It reviewed 100%
of data to detect missing or inconsistent data to generate queries to
the investigators for resolution. In addition to this, Medtronic
Bakken Research Centre BV (Maastricht, the Netherlands) randomly
monitored over 40% of patients’ source documentation against the
data entered. They also performed a veriﬁcation of all 1262 patient
informed consents and essential study documents at each site.
All variables are reported descriptively with no hypothesis
testing. For categorical variables, frequency and percentage were
calculated. For continuous variables, mean, standard deviation,
minimum and maximum were calculated. A per protocol analysis
was performed for the technical observations. All other variables
were evaluated on an intention-to-treat basis.
Results
FromMarch 2009 until April 2011, 1266 patients from 79 sites in
30 countries were initially recorded in the database. Four patients
however, were excluded from the study for the following reasons;
one patient refused immediate treatment, but underwent emer-
gency EVAR for a ruptured AAA 3 months later; one patient
underwent open surgical treatment instead, because of unsuitable
anatomy on preoperative imaging; one patient was operated on at
a non-participating site; and with one patient, the informed
consent form was missing. Data for the remaining 1262 patients
comprise the basis of this report. At time of writing, a sub-cohort of
the ﬁrst 500 operated patients (39.6%) had the opportunity to
complete 12-month follow-up. Their data form the basis of the 1-
year outcome analysis.
Baseline characteristics
Patients’ demographics and risk factors (Table 2) were typical of
an AAA population. They were predominantly male, elderly and
American Society of Anaesthesiologists (ASA) class II or III, with
a high prevalence of cardiovascular risk factors and co-morbidities.
The primary indication for EVAR was an AAA diameter >5 cm in
88.1% of cases and 83.9% of patients were asymptomatic. Table 3
describes baseline aneurysm characteristics. The mean maximum
AAA diameter was 60.3  11.7 mm. The proximal aortic neck had
a mean diameter of 23.7  3.6 mm, with a non-aneurysmal length
of 27.0  12.4 mm (27 (2.2%) patients with neck length <10 mm)
and a mean infrarenal neck angulation of 30.3 23.8. Notably, 226
patients (17.9%) were implanted outside the IFU criteria (Table 4).Intra-operative outcome
The procedure was performed under general, regional and local
anaesthesia in, respectively, 62.3%, 26.2% and 11.5% of cases. The
mean procedural duration was 99.5  45.0 min (range
20e387 min), with a mean total ﬂuoroscopic time of
20.5  12.4 min (range 0e92 min) and a mean contrast volume
used of 130.7  70.6 ml (range 0e400 ml). Mean intra-operative
blood loss was 208.4  220.1 ml (range 0e2700 ml). ICU admis-
sion rate was 34.2%, and 6.0% were admitted longer than 24 h. The
Table 4
Patients implanted outside IFUa (ITT analysis).
Variable N ¼ 1262
Total implanted outside of IFUa guidance 17.9% (226/1262)
Non-primary indications 2.3% (29/1262)
Proximal neck diameter < 19 mm or >32 mm 5.7% (72/1255)
Proximal neck length < 10 mm 2.2% (27/1248)
Proximal neck length  10 mm and <15 mmb 2.1% (26/1248)
Angulation suprarenal > 60 or infrarenal > 75 4.7% (59/1248)
Distal iliac ﬁxation site diameter <8 mm 1.5% (19/1262)
Distal iliac ﬁxation site diameter >25 mm 0.6% (8/1262)
a Instructions for use.
b In combination with suprarenal angle > 45 or infrarenal angle > 60 .
Table 5
Initial procedural data and evaluation (ITT & PP analysis).
Placement procedure (ITT) N ¼ 1262
Pre-implant adjunctive procedure performed 7.6% (96/1262)
Coil embolization IIAa 4.3% (54/1262)
Coil embolization IMAb 1.1% (14/1262)
Other 2.4% (30/1262)
Associated procedures performed during procedure
Coil embolization IIA 5.1% (64/1262)
Coil embolization IMA 0.6% (7/1262)
Other 8.7% (110/1262)
None 86.5% (1091/1262)
Additional device used during implant procedure
Balloon catheter 76.5% (965/1262)
Unplanned 6.0% (76/1262)
Stent (other than Endurant) 6.2% (78/1262)
Unplanned 3.5% (44/1262)
Other 6.8% (86/126)
Placement of proximal end of device
With suprarenal stent crossing both renal arterie 75.7% (955/1262)
With suprarenal stent crossing one renal artery 6.0% (76/1262)
Below both renal arteries 17.5% (221/1262)
Placement of distal end of device
Right limb distal to the IIA 8.8% (111/1262)
Left Limb distal to the IIA 8.3% (105/1262)
Endurant stent-graft implanted into a patient 99.5% (1256/1262)
2 components implanted 43.0% (540/1256)
3 components implanted 27.5% (345/1256)
4 components implanted 21.9% (275/1256)
5 components implanted 6.6% (83/1256)
Primary effectiveness endpoints (ITT) N ¼ 1262
Technical success 99.0% (1250/1262)
Endurant stent-graft successfully delivered 99.4% (1255/1262)
Endurant stent-graft successfully deployed 99.4% (1255/1262)
No unintended coverage of IIA or any VABsc 99.5% (1253/1259)
Endurant delivery system successfully removed 99.9% (1261/1262)
Intra-operative clinical success 97.6% (1232/1262)
Technical success 99.0% (1250/1262)
Freedom from intra-operative death 100.0% (1262/1262)
Freedom from type I/III endoleak 98.6% (1238/1256)




Wire form fracture 0.0% (0/1253)
Suprarenal bare stent fracture 0.0% (0/1253)
Other malfunctions 0.3% (4/1256)
Endoleak (Uncorrected)d 16.0% (201/1256)
Type I 1.1% (14/1256)
Type II 12.4 % (156/1256)
Type III 0.3% (4/1256)
Type IV 1.8% (22/1256)
Undetermined 0.7 % (9/1256)
a Internal iliac arteries.
b Inferior mesenteric arteries.
c Visceral aortic branches.
d Uncorrected: Detected, but chosen not to treat within initial procedure.
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4.83  5.07 days (median 4.00; range 0.5e68 days).
Technical success was achieved in 1250 patients (99.0%). The
Endurant was delivered to the planned location and successfully
deployed in 99.4% of patients (Table 5). Attempts at endovascular
repair were discontinued in six (0.5%) patients: four cases with
access problems due to tortuous or stenotic iliac arteries, two of
whomwere eventually converted to open repair after 2 and 49 days
respectively. One patient required immediate conversion after
unintentional coverage of both renal arteries, when the suprarenal
stent was released before accurate placement of the covered stent.
In another case, one of the proximal struts got stuck in the tip-
capture portion of the delivery system, resulting in the inability
to remove the device and necessitating immediate conversion to
open surgery. There were no intra-operative deaths.
Adjunctive procedures were performed before or during
implant procedures in 96 (7.6%) and 171 (13.5%) cases, respectively
(Table 5). Primarily coil embolisation of the internal iliac artery or
inferior mesenteric artery. Unplanned additional stents (other than
Endurant) were placed in 44 (3.5%) patients, mainly to resolve
intra-operative type-I/III endoleaks. The ﬁnal completion angio-
gram revealed type-I and type-III endoleaks in 14 (1.1%) and four
(0.3%) cases, respectively, predominantly in patients with regular
neck conﬁgurations. Among patients with type-I endoleaks, one
patient underwent secondary placement of a proximal cuff.
Another patient died of a myocardial infarction before 30-day
imaging was performed. In all remaining cases, the endoleaks
were absent at 30-day CTA and no secondary interventions were
performed.
Perioperative outcome
One-month imaging was performed in 91.6% of the 1256
implanted patients (Table 6). One or more graft-related problems,
including endoleaks, were reported in 191 (16.6%) of these patients.
Occlusion of one of the iliac limbswas reported in 23 patients (2.0%)
and graft stenosis was detected in 16 (1.4%). Stent graft kinking
occurred in 20 (1.7%) cases. One report of occlusion of a (right) renal
artery occurred. This did not result in major clinical event or re-
intervention. There were no stent fractures or stent graft migra-
tions reported in any patient through 30 days.
Endoleaks were present in 138 (12.0%) patients at 30 days, of
which in seven cases the type could not be speciﬁed. type-I and/or
-III endoleaks were identiﬁed in 17 (1.5%) patients, including one
patient with both types present. One of the type-I endoleaks had
been observed at the time of operation and persisted to day 32,
when it was successfully treated. The remaining endoleaks were
newly diagnosed on the 30-day imaging study. Among these, eight
type-I endoleaks were treated with an extension or remodelling of
the graft, four spontaneously resolved without intervention and
two had not yet reached the 12-month follow-up visit. The patientwith both a type-I and -III endoleak present had persistent endo-
leaks at the 12-month images, and was scheduled for re-
intervention thereafter. The other type-III endoleak was resolved
on follow-up images.
The overall 30-day mortality rate was 1.3. One or more major
adverse events within 30 days, including all-cause mortality, were
reported in 3.9% of patients (Table 7); bowel ischaemia was recor-
ded in three patients (0.2%), myocardial infarction in 14 patients
(1.1%), renal failure in four patients (0.3%), stroke in two patients
(0.2%) and blood loss 1000 cc was recorded in 18 (1.4%) patients.
No patient developed paraplegia or respiratory failure.
Within the ﬁrst month, three (0.2%) cases were converted to
open surgery, two as emergencies and one electively, as mentioned
earlier. Secondary interventions were required in 19 (1.5%) cases,
Table 6
Technical performance at 30-days (PP analysis).
Variable N ¼ 1151a
One or more technical observations 16.6% (191/1151)
Stent graft kinking 1.7% (20/1151)
Stent graft twisting 0.1% (1/1151)
Stent graft wire form fracture 0.0% (0/1151)
Suprarenal bare stent fracture 0.0% (0/1151)
Suprarenal bare stent detachment from fabric 0.1% (1/1151)
Stent graft occlusion 2.0% (23/1151)
Stent graft stenosis 1.4% (16/1151)
Stent graft migration 0.0% (0/1151)
Endoleak 12.0% (138/1151)
Type I 1.4% (16/1151)
Type II 9.9% (114/1151)
Type III 0.2% (2/1151)
Type IV 0.1% (1/1151)
Undetermined 0.6% (7/1151)
Type I and/or III 1.5% (17/1151)
Other technical observation 0.6% (7/1151)
a Only implanted patients with 1-month imaging study included in the analyses.
Figure 1. KaplaneMeier estimates for all-cause mortality & AAA-related mortality.
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endovascular intervention for graft occlusion, stenosis or kinking;
one case was for contralateral leg implant; six (0.5%) cases required
a bypass procedure; and four (0.3%) cases required endovascular
intervention to correct a type-I endoleak.
One-year outcome
A sub-cohort of 500 patients was followed for at least 12
months, with compliance to follow-up of 98.6%. Baseline charac-
teristics and perioperative outcome measures of this sub-cohort
were comparable to those of the total study population. There-
fore, further analysis on this sub-cohort was considered to be
valuable.
The 1-year KaplaneMeier estimate for overall survival was
91.6  1.4%. The 1-year estimate for aneurysm-related survival was
98.8  0.5%, with no device-related deaths (Fig. 1). One or more
MAEs, including all-cause mortality, were reported in 11.2% of
patients within 1-year follow-up; including ﬁve (1.0%) cases of
renal failure, nine (1.8%) myocardial infarctions, two (0.4%) cases of
stroke, two (0.4%) case of bowel ischaemia and one (0.2%) case of
respiratory failure.
The KaplaneMeier estimate for 1-year secondary intervention-
free survival was 95.1  1.1% (Fig. 2). Within the ﬁrst year after
implantation, secondary interventions were required in 23 (4.6%)
patients. Endovascular procedures were performed in 10 patients
to resolve graft occlusion, stenosis or kinking; in six patients toTable 7
Patient outcome within 30-days (ITT analysis).
Variable N ¼ 1262
One or more major adverse events (MAE) 3.9% (49/1262)
All-cause mortality 1.3% (16/1262)
Bowel ischemia 0.2% (3/1262)
Myocardial infarction 1.1% (14/1262)
Paraplegia 0.0% (0/1262)
Renal failure 0.3% (4/1262)
Respiratory failure 0.0% (0/1262)
Stroke 0.2% (2/1262)
Procedural blood loss 1000 cc 1.4% (18/1262)
Conversion to open surgery 0.2% (3/1262)
Secondary surgical procedure 1.5% (19/1262)
Endovascular for occlusion, stenosis or kinking 0.6% (8/1262)
Endovascular to correct Type I/III endoleak 0.3% (4/1262)
Open bypass procedure 0.5% (6/1262)
Other 0.1% (1/1262)
Aneurysm rupture 0.0% (0/1262)correct a type-I/III endoleak; and in three patients to resolve
a persistent type-II endoleak. Five patients underwent a by-pass
procedure for an occluded iliac limb. Notably, stent graft migra-
tion or loss of device integrity was never observed within the ﬁrst
year after implantation. In addition, there were no reports of
aneurysm rupture. At 1-year, aneurysm size increased by5mm in
2.8% of cases, was stable in 55.9% of cases and decreased by 5 mm
in 41.3% of cases.
Discussion
The technology of EVAR for AAAs is a dynamic, ever-changing
endeavour. The challenge is to decrease complications and re-
interventions while safely treating more complex anatomy, espe-
cially for those cases unﬁt for open repair. As improved devices
with wider inclusion criteria become available and operators
become more proﬁcient with endovascular techniques, the
proportion of patients suitable for EVAR increases.13 However,
overall outcomes may not improve if broadening the application
rate results in poorer outcomes despite improvements in operator
skill and device design. This ever-evolving trade-off implies that
results from older series using previous generations of devices mayFigure 2. KaplaneMeier estimates for secondary procedures.
R.A. Stokmans et al. / European Journal of Vascular and Endovascular Surgery 44 (2012) 369e375374not reﬂect the current status of EVAR. As a consequence, results of
the performance of latest generation devices in contemporary, real-
world settings are important. High-quality, well-designed obser-
vational studies are increasingly believed to provide complemen-
tary evidence to randomised controlled trials (RCTs).14 Therefore,
they are essential in making a balanced judgement about the
management of AAAs.
The ENGAGE registry was undertaken to quantify the perfor-
mance of a recently released endograft within the context of
contemporary, real-world use. This prospective observational study
represents the collective experience of 79 centres in 30 countries
across ﬁve different continents with the Endurant Stent Graft. As
eligibility was for the most part, left to the discretion of the
investigator, the outcomes in the 1262 AAA patient series are ex-
pected to have high external validity. Follow-up protocols were
kept as close as possible to standard site regimens, to keep treat-
ment to real world practice. In order to be able to produce mean-
ingful analysis, a large quantity of data was recorded. To guarantee
high quality and completeness of data, efforts were made to ach-
ieve onsite quality control and continual monitoring of reported
data, which is evident in the high level of compliance to follow-up
in this registry.
The necessity for secondary interventions is considered the
Achilles’ heel of EVAR.18,19 Secondary interventions were the main
reason that EVAR was not considered cost-effective at long-term
follow-up in the DREAM (Dutch Randomised Endovascular Aneu-
rysm Management) trial.20 A re-intervention rate of 4.6% is compa-
rable to re-intervention rates of earlier reports and the recent OVER
(Open Versus Endovascular Repair) trial, and compares favourably to
the landmark studies EVAR 1 (Endovascular Repair versus Open
Repair) andDREAM.5e7,15e17 The type II endoleak rate of 9.9%,which is
remarkably lower than in these older studies,might have contributed
to the lower rate of secondary procedures. Comparison of re-
intervention rates at 1-year with other studies is hampered by
several factors; in particular, the treatment of type-II endoleaks has
changedover time.Ontheotherhand, in theENGAGERegistry,17.9%of
patientswere treated outside IFU, primarily due to complex anatomy;
therefore, it should also be taken into consideration that the eligibility
criteria for ENGAGE were less strict than for DREAM and OVER.6,7
The majority of re-interventions in our study were performed
for iliac limb occlusion or stenosis. Van Keulen et al.17 also found
a higher iliac limb occlusion rate together with a 1-year re-
intervention rate of 5% after implantation of an Endurant Stent
Graft. At this moment, we are unable to conclude if there is any
causality between occurrence of iliac occlusions and the wider
inclusion criteria associated with the Endurant Stent Graft, or the
stent graft itself.
Despite numerous cases of short- or angulated necks, rates of
early type-I endoleaks were low, with no ruptures and 42% of re-
ported aneurysm-sac shrinkage. So far, few re-interventions were
required to resolve endoleaks. A comparison with the literature on
type-I/III re-interventions or shrinkage of the aneurysm awaits
availability of longer-term follow-up.
Compared with the landmark studies EVAR-1 and DREAM, in
this study both perioperative mortality and the aneurysm-related
mortality rates after 1 year were comparable. The all-cause
mortality rate in this study compares favourably to EVAR-1 and
DREAM.5,6 This is remarkable given the proportion of ASA class IV
patients (10.6%) in the ENGAGE study population; in all previously
assessed RCTs, ASA class IV patients were excluded.
Conclusion
ENGAGE is an unprecedented registry in scope and magnitude
to characterise the performance of the Endurant Stent Graft ina contemporary series of 1262 AAA patients treated with the stent
graft in 30 countries. The early results of the Endurant Stent Graft in
a real-world, global experience are promising despite the fact that
10.6% of patients were classiﬁed ASA class IV and 17.9% of the
patients were treated outside IFU. Longer follow-up is needed to
assess durability of safety and effectiveness in a broader spectrum
of AAA patients treated via endovascular methods.
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Appendix A
ENGAGE Participating investigators and centres. Argentina.
Ricardo D. Garcia e Monaco, MD, PhD, Italian Hospital, Buenos
Aires; Jaime Camacho, MD, Fundacion Favaloro, Buenos Aires.
Australia. Rob Fitridge, MD, PhD, Queen Elizabeth Hospital,
Adelaide/St Andrews Hospital, Adelaide; Michael J. Grigg, MD,
PhD, Box Hill Hospital, Melbourne; Steve Dubenec, MD, Royal
Prince Alfred Hospital, Camperdown; Nick Boyne, MD, Royal
Brisbane and Womens Hospital, Brisbane; Michael J. Grigg, MD,
PhD, Eastern Epworth Healthcare, Melbourne; Patrice B. Mwi-
patayi, MD, Royal Perth Hospital, Perth/Hollywood Private
Hospital, Nedlands. Austria. Thomas Rand, MD, PhD, Hietzing
Hospital, Vienna. Belgium. Patrick J. Peeters, MD, Imelda
Hospital, Bonheiden; Jeroen M.H. Hendriks, MD, PhD, University
Hospital, Antwerp; Marc Bosiers, MD, St. Blasius Hospital, Den-
dermonde; Frank Vermassen, MD, PhD, University Hospital,
Ghent. Canada. Thomas L. Forbes, MD, London Health Sciences
Centre Victoria Hospital, London; Min Lee, MD, Queen Elisabeth
II Health Sciences Centre, Halifax; Leonard W.H. Tse, MD, Toronto
General Hospital, Toronto; Yvan Douville, MD, Hospital Saint
Francois d`Assise, Québec; Oren K. Steinmetz, MD, McGill
University, Royal Victoria Hospital, Montréal. China. Jichun Zhao,
MD, PhD, Hua Xi Hospital (West China Hospital), Sichuan; Jian-
fang Luo, MD, Guangdong General Hospital, Guangzhou; Wei
Guo, MD, 301 PLA General Hospital, Bei Jing. Colombia. Jaime
Camacho, MD, Fundacion Cardioinfantil, Bogota. Czech Republic.
Jiri Novotny, MD, PhD, Institute for Clinical and Experimental
Medicine, Prague. France. Jean-Pierre Becquemin, MD, Henri
Mondor Hospital, Paris; Dominique Midy, MD, PhD, Pellegrin
Hospital, Bordeaux; Emmanuel M. Choukroun, MD, Cardiology
Hospital of Haut-Leveque, Pessac. Germany. Giovanni Torsello,
MD, PhD, St Franziskus Hospital, Münster; Dittmar Böckler, MD,
R.A. Stokmans et al. / European Journal of Vascular and Endovascular Surgery 44 (2012) 369e375 375PhD, University Clinic, Heidelberg; Gerhard Hoffmann, MD, City
Hospital, Solingen. Greece. Kostantinos O. Papazoglou, MD, PhD,
Kianous Stavros Clinic, Thessaloniki; Dimitris A. Kiskinis, MD,
Papageorgiou Hospital, Thessaloniki. Hong Kong. Stephen W.K.
Cheng, MD, PhD, Queen Mary Hospital, Hong Kong. Israel.
Yehuda G. Wolf, MD, Sourasky Medical Center, Tel Aviv. Italy.
Andrea Stella, MD, S. Orsola e Malpighi Policlinic Hospital,
Bologna; Carlo Setacci, MD, Le Scotte Policlinic Hospital, Siena;
Carlo Pratesi, MD, Careggi Hospital, Florence. Korea. Do Yun Lee,
MD, PhD, Yonsei Severence University Hospital, Seoul; Jae Kyu
Kim, MD, PhD, Chonnam National University Hospital, Gwangju.
Lithuania. Valdas Bilkis, MD, Vilnius University Hospital San-
tariskiu Klinikos, Vilnius. New Zealand. Andrew G. Hill, MD,
Auckland City Hospital, Auckland; Thodur Vasudevan, MD, Wai-
kato DHB Hospital, Hamilton. Norway. Eric J. Dorenberg, MD,
Rikshospitalet University Hospital, Oslo; Rolf Busund, MD, PhD,
University Hospital North-Norway, Troms; Guttorm L. Jenssen,
MD, Haukeland University Hospital, Bergen. Poland. Walerian
Staszkiewicz, MD, PhD, Bielanski Hospital, Warsaw; Piotr
Gutowski, MD, PhD, Samodzielny Public Hospital Clinic 2,
Poznan. Portugal. Joao Albuquerque e Castro, MD, Santa Marta
Hospital, Lisbon. Slovakia. Ivan Vulev, MD PhD, Institute of
Cardiovascular Diseases, Bratislava. South Africa. Jacobus Van
Marle, MD, Unitas Hospital, Centurion; Corstiaan Leendert Punt,
MD, St Georges Hospital, Port Elizabeth; Phillip J. Matley, MD,
Kingsbury Hospital, Cape Town. Spain. Aurelio Garcia e de la
Torre, MD, University Hospital Central e Asturias, Oviedo; Vin-
cente Riambau, MD, PhD, University of Barcelona Hospital Clinic,
Barcelona; Francisco J. Gomez e Palonés, MD, Peset University
Hospital, Valencia; Carlos Vaquero e Puerta, MD, PhD, University
Hospital, Valladolid; Eduardo Ros, PhD, San Cecilio University
Hopspital, Granada. Sweden. HåkanRoos, MD, Sahlgrenska
University Hospital, Gothenburg; Martin Delle, MD, PhD,
Sodersjukhuset, Stockholm; Thomas Larzon, MD, Orebro
University Hospital, Orebro. Switzerland. Do Dai-Do, MD, PhD,
Inselspital, University Hospital, Berne. Thailand. Boonprasit
Kritpracha, MD, Songklanagarind Hospital, Songkhla. The
Netherlands. Joep A.W. Teijink, MD, PhD, Catharina Hospital,
Eindhoven; Hence J.M. Verhagen, MD, PhD, Erasmus Medical
Center, Rotterdam; Steven M.M. van Sterkenburg, MD, Rijnstate
Hospital, Arnhem; Rob Welten, MD, PhD, Atrium Medical Center,
Heerlen; Jan M.M. Heijligers, MD, PhD, St. Elisabeth Hospital,
Tilburg; Jean-Paul P.M. de Vries, MD, PhD, St. Antonius Hospital,
Nieuwegein. Turkey. A. Yigit Göktay, MD, Dokuz Eylül University
Hospital, Izmir; Levent Oguzkurt, MD, Adana Baskent University
Hospital, Adana; Furuzan Numan, MD, PhD, Memorial Hospital,
Istanbul/Istanbul University Cerrahpasa, Istanbul. United
Kingdom. Paul D. Hayes, MD, Addenbrooke’s Hospital, Cam-
bridge; John Rose, MD, Freeman Hospital, Newcastle upon Tyne;
Richard G. McWilliams, MD, Royal Liverpool University Hospital,
Liverpool; Ray Ashleigh, MD, Wythenshawe Hospital, Man-
chester; Matt Thompson, MD, PhD, St George’s Hospital Tooting,
London. Uruguay. Carmelo Gastambide, MD, Medical Corpora-
tion Uruguaya, Montevideo.References
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